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Abstract
Purpose Enzastaurin, an oral serine/threonine kinase
inhibitor, targets the protein kinase C and AKT pathways
with anti-tumor and anti-angiogenic effects. Erlotinib, an
oral epidermal growth factor receptor (EGFR) inhibitor,
has activity in solid tumors. Based on the promising com-
binationofEGFR inhibitors andanti-angiogenicagents,this
phase I trial was initiated.
Methods This single-institution, open-label, non-ran-
domized trial used a standard 3 ? 3 dose-escalation model
in patients with advanced solid malignancies including
non-small-cell lung cancer (NSCLC). Two dose levels of
enzastaurin (with loading doses) were explored: 250 mg
dailyand500 mgdaily.Erlotinibwasgivenat150 mgdaily.
Results Sixteen patients were enrolled in this study
(median age, 64 years). Most patients were heavily pre-
treated, female, and Caucasian and had NSCLC. The
highest dose of enzastaurin, 500 mg daily, was tolerated
with no unexpected adverse events and no alteration in the
pharmacokinetics of either drug at this dose level. The
mean clearance was 5.75 L/h for erlotinib and 53.8 L/h for
enzastaurin. The most common possibly drug-related grade
3–4 adverse events included diarrhea (25.0%), neurologic
symptoms (18.8%), and vomiting (18.8%). Activity was
noted, with a partial response in one patient and prolonged
disease stability for[12 cycles in three patients.
Conclusion The combination of enzastaurin 500 mg daily
and erlotinib 150 mg daily is well tolerated and does not
alter the pharmacokinetics of the individual drugs, with
clinical activity seen. A phase II trial of this combination
has been initiated in patients with advanced-stage NSCLC.
Keywords Clinical trial  Enzastaurin  Erlotinib 
Pharmacokinetics
Introduction
The treatment of solid tumors with targeted agents has
shown promise, particularly with inhibitors of the epider-
mal growth factor receptor (EGFR) and angiogenic path-
ways. Enzastaurin, a novel targeted agent in the class of
acyclic N-(azacycloalkyl) bisindolylmaleimides, is an oral
serine/threonine kinase inhibitor that targets both the pro-
tein kinase C (PKC) and AKT pathways [1, 2]. PKC and
AKT have been associated with tumorigenesis, treatment
efﬁcacy, and outcome in a variety of cancers, including
non-small-cell lung cancer (NSCLC) [3–5]. In preclinical
models, anti-tumor and anti-angiogenic activity of enzas-
taurin was demonstrated in various cancer cell lines and
human cancer xenografts (including lung cancer) [2, 6]
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well tolerated up to 700 mg with early promising activity
[7]. In a phase II study, single-agent enzastaurin as second-
or third-line therapy in patients with metastatic NSCLC
was well tolerated with some disease stabilization seen
(11% with prolonged stabilization[6 months) [8].
Erlotinib, an EGFR-targeted tyrosine kinase inhibitor,
has been shown to increase overall survival when com-
bined with gemcitabine in pancreatic cancer [9] and as a
second- or third-line single agent in NSCLC [10]. In
NSCLC, erlotinib increased the response rate (8.9% vs.
\1%, P\0.001) and overall survival (6.7 months vs.
4.7 months; hazard ratio, 0.70; P\0.001) compared with
placebo in an unselected patient population [10].
Mechanisms of resistance to EGFR inhibitors include
activation of the phosphoinositide 3-kinase (PI3 K)/AKT
pathway [11, 12] and increased secretion of angiogenic
factorsincludingvascularendothelialgrowthfactor(VEGF)
[13]. Because enzastaurin suppresses VEGF-mediated angio-
genesis through PKCß inhibition and inhibits the PI3
K/AKT pathway, it was hypothesized that the combination
of erlotinib and enzastaurin would offer a mechanistic
advantage. In preclinical models combining enzastaurin
with geﬁtinib, an EGFR inhibitor similar in mechanism to
erlotinib, synergism was found in a variety of both geﬁti-
nib-sensitive and geﬁtinib-resistant cancer cell lines [14].
In previous studies, when administered in combination
with other agents, enzastaurin did not lead to an increased
toxicity proﬁle [15, 16]. Based on these promising data and
the expected effectson commonsignalingpathways, a phase
I/II study was initiated to evaluate the combination of en-
zastaurin and erlotinib; phase I results are presented here. As
both drugs are metabolized through the liver cytochrome
p450CYP3A4[7,17],adose-escalationtrialwasdesignedto
ensure that there were no signiﬁcant drug–drug interactions.
TheprimaryobjectiveofthephaseIportionofthetrialwasto
determinetherecommendedphaseIIdoseofthecombination
oferlotinibandenzastaurininpreviouslytreatedpatientswith
advanced NSCLC and other advanced solid malignancies;
secondary objectives included evaluation of the pharmaco-
kinetic interaction between enzastaurin and erlotinib and the
safety of the combination.
Methods
Eligibility criteria
Eligible patients included those with an incurable solid
malignancy; no more than three prior systemic treatment
regimens for advanced disease; an Eastern Cooperative
Oncology Group (ECOG) performance status of 0, 1, or 2;
an estimated life expectancy of at least 2 months; non-
measurable or measurable disease deﬁned by Response
Evaluation Criteria in Solid Tumors (RECIST) [18]; ade-
quate hematologic function including white blood cell
count C3.0 9 10
9/L, absolute neutrophil count C1.5 9
10
9/L, platelet count C75.0 9 10
9/L, and hemoglobin
C10.0 g/dL; adequate hepatic function including bilirubin
B1.5 times the upper limit of normal (ULN) and alkaline
phosphatase, aspartate transaminase, and alanine transam-
inase B2.5 times the ULN, or\5 times the ULN with liver
metastases; and adequate renal function with serum creat-
inine B1.5 times the ULN. Patients who were unable to
swallow tablets, unable to stop taking enzyme-inducing
anti-epileptic drugs, or were previously treated with an
EGFR inhibitor or enzastaurin were excluded from the
study. Patients with symptomatic interstitial lung disease, a
serious heart condition, second primary cancer, or who
were pregnant or breast feeding were also excluded.
Patients with central nervous system metastases were
allowed only if they had completed local therapy and were
off corticosteroids for at least 4 weeks. Prior chemotherapy
or radiotherapy had to be completed at least 2 weeks before
study enrollment and surgical intervention at least 4 weeks
before enrollment.
The study protocol and informed consent were approved
by the Stanford Institutional Review Board. All patients
signedaninformedconsentdocumentincompliancewiththe
DeclarationofHelsinkiandgoodclinicalpracticeguidelines.
Study design and treatment plan
This was a single-institution, open-label, non-randomized,
phase I clinical trial that used a standard 3 ? 3 dose-
escalation model with two planned doses of enzastaurin.
Dose-limiting toxicity (DLT) was deﬁned as the fol-
lowing events that occurred during cycle 1 according to the
National Cancer Institute’s Common Terminology Criteria
for Adverse Events (NCI-CTCAE, version 3.0): grade 4
hematologic events and grade 3 or 4 non-hematologic
events except those that could be explained from a coex-
isting condition or events of nausea, vomiting, diarrhea, or
skin rash that were controlled with supportive treatment.
All patients received oral enzastaurin (Eli Lilly and
Company, Indianapolis, IN) and erlotinib (OSI, now
Astellas/Genentech/Roche, Melville, NY) daily. Cycles
were 28 days long. Enzastaurin was taken 30 min after a
meal and erlotinib was taken 1 h before a meal in the ﬁrst
cycle;insubsequentcycles,erlotinibcouldbetaken2 hafter
a meal, as long as the timing of dosing was consistent. All
cohorts received erlotinib 150 mg daily, the standard dose
given as a single agent for advanced-stage NSCLC [10].
Cohort 1 was designed to include three patients at dose
level 1: enzastaurin 250 mg daily with a loading dose of
500 mg on day 1 (given as 250 mg two times a day). All
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123three patients had to complete cycle 1 of dose level 1
without a DLT before enrolling an additional three patients
at dose level 2, the full enzastaurin dose of 500 mg daily
with a loading dose of 1125 mg on day 1 (given as 375 mg
three times a day) [7]. If all three patients tolerated dose
level 2 without a DLT, enrollment continued up to 12
patients at the maximum tolerated dose to complete the
pharmacokinetic analysis and more fully explore the dose
before initiating phase II. However, if one patient experi-
enced a DLT at any dose level, the cohort was to be
expanded to six patients. If no more than one patient within
the expanded cohort of six patients experienced a DLT, the
dose level could be escalated to the next higher dose. If two
or more of the six patients experienced a DLT, the next
lower dose level was the recommended dose. Patients
continued study treatment until disease progression or
unacceptable toxicity.
Treatment assessments
Patients were evaluated weekly for the ﬁrst cycle and then
every 28 days for subsequent cycles through a 30-day post-
discontinuation period. Treatment compliance by pill count
was performed at each visit, and adverse events (AEs) were
monitored and graded before each cycle using the NCI-
CTCAE version 3.0. AEs were reported regardless of relat-
edness to study treatment or procedure from the time of
enrollment through the post-discontinuation period. At each
visit, recording of patient’s concomitant medications; phys-
ical examination; assessment of any AEs and ECOG per-
formance status; and routine laboratory testing including
complete blood count, chemistry, and coagulation studies
wereperformed.Pre-treatmentstudiesalsoincludedbaseline
imaging (computed tomography or magnetic resonance
imaging) B28 days before enrollment. Although this study
was not designed to assess efﬁcacy, repeat imaging was
performed and evaluated using RECIST every two cycles.
Pharmacokinetics
Blood samples for pharmacokinetic evaluations were col-
lectedatday22 ± 3 daysofcycle1forbothenzastaurinand
erlotinib. Plasma samples of 3 and 1 mL were used for en-
zastaurin (and its metabolite, LY326020) and for erlotinib,
respectively. The collection times for enzastaurin were pre-
dose and 2, 4, 6, and 8 h post-dose. The collection times for
erlotinib were pre-dose and 2, 4, 6, and 10 h post-dose.
Pharmacokinetic parameters were computed using non-
compartmental analysis using WinNonlin
 Professional
Edition version 5.0.1 (Pharsight, Mountain View, CA). The
maximum steady-state plasma concentration (Cmax,ss), time
to maximum steady-state plasma concentration (tmax,ss),
area under the concentration–time curve of the dosing
interval (AUCs,ss), and average steady-state concentration
(Cav,ss) were calculated for enzastaurin, its metabolite
(LY326020), and erlotinib. The apparent clearance of en-
zastaurin and erlotinib at steady state (CLss/F) was calcu-
lated as well as the metabolic ratio for LY326020, which
was calculated using the ratio of the AUCmetabolite,ss to
AUCparent,ss. Enzastaurin Cav,ss and erlotinib CLss/F were
compared with historical data [7, 19].
Results
Patients and treatment received
Sixteen patients were enrolled and treated in this study
(median age of 64 years; range, 46–83 years) from May
2007 to June 2009 (Table 1). Most patients were female
(n = 13) and Caucasian (n = 11). The majority (n = 9)
had NSCLC and an ECOG performance status of 0 (n = 5)
or 1 (n = 10), and patients had received one (n = 5), two
(n = 7), or three (n = 4) prior chemotherapy regimens.
The majority of patients (n = 15) discontinued the study
due to disease progression. One patient decided to stop
therapy during cycle 2 for personal reasons. Fifteen
patients completed at least two cycles of therapy. Four
patients completed 12 cycles or more, with one patient
Table 1 Baseline patient demographics (n = 16)
Demographics No. of patients
Sex
Female 13
Male 3
Median age (range), years 64 (46–83)
Ethnicity
Caucasian 11
East Asian 4
Hispanic 1
ECOG performance status
05
11 0
21
Tumor type
NSCLC 9
Sarcoma, GIST, parotid carcinoma,
cholangiocarcinoma, biliary papillomatosis,
thyroid cancer, HCC
7
Smoking history
Yes (current/past) 8
No 8
ECOG Eastern Cooperative Oncology Group; N total population size;
NSCLC non-small-cell lung cancer; GIST gastrointestinal stromal
tumor; HCC hepatocellular carcinoma
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123receiving 14 cycles before developing progressive disease.
The mean number of cycles received was 4.6 and the
median was 2 (range, 1–14).
Recommended dose
Of three patients initially enrolled at dose level 1 (erlotinib
150 mg daily and enzastaurin 250 mg daily after the
loading dose), one patient discontinued in cycle 1 due to
rapid and fatal disease progression. This patient was
replaced in the cohort. After no DLTs occurred in this
cohort, dose level 2 was initiated and, as no DLTs occur-
red, a total of 12 patients were enrolled at dose level 2 as
planned. Dose level 2 was the recommended phase II dose
level (i.e., erlotinib 150 mg daily and enzastaurin 500 mg
daily after the loading dose).
Safety and tolerability
AEs regardless of causality that occurred in C25% of
patients are presented in Table 2. The most common AEs,
regardless of relationship to treatment, were diarrhea,
chromaturia, rash, decreased appetite, feces discoloration,
and nausea. One patient in dose level 1 and 9 patients in
dose level 2 experienced non-laboratory grade 3 or higher
AEs possibly related to study drug. These AEs included
anorexia, ataxia, diarrhea, diplopia, dizziness, pruritus, and
vomiting (Table 3). No patient experienced grade 3–4
laboratory AEs possibly related to study drug. Serious AEs
considered possibly drug-related were ataxia, diplopia, and
drug interaction in one patient and balance disorder and fall
in one patient. Other serious adverse events reported that
were considered unrelated to treatment included one
patient with a gastrointestinal stromal tumor who had a
pulmonary embolism and deep vein thrombosis.
There were no deaths or discontinuations due to drug-
related AEs while on study. Three deaths (one in dose level
1 and two in dose level 2) occurred within 30 days of
discontinuation due to disease progression.
Pharmacokinetics
The mean Cav,ss at dose level 2 for enzastaurin and its
active metabolite LY326020 was 750 nmol/L (n = 12) and
751 nmol/L(n = 12), respectively,after 22 days(±3 days)
of 500-mg daily doses of enzastaurin with 150-mg daily
doses of erlotinib.
The mean AUCs,ss was 18,000 nmol 9 h/L (n = 12) for
both enzastaurin and its active metabolite LY326020 after
22 days (±3 days) of 500-mg daily doses of enzastaurin
with 150-mg daily doses of erlotinib. The mean clearance
(CLss/F) of enzastaurin was 53.8 L/h (n = 12). A summary
of all steady-state pharmacokinetic parameters is shown in
Table 4. The high variability for pharmacokinetic param-
eter estimates in the 250-mg dose group is due to a patient
who had very high concentrations compared with the other
two patients in the group.
The mean steady-state pharmacokinetic parameters for
erlotinib 150 mg daily with 250- or 500-mg daily doses of
enzastaurin are summarized in Table 5. The mean clear-
ance (CLss/F) of erlotinib was 6.07 L/h when given with
250 mg of enzastaurin and 5.75 L/h when given with
500 mg of enzastaurin. Data from one patient in dose level
2 were excluded from the analysis due to an error in the
dose record.
Themeansteady-stateplasmaconcentration–timeproﬁles
of erlotinib (after 150-mg daily doses with 250- or 500-mg
daily doses of enzastaurin) and total analyte (enzastau-
rin ? LY326020, following 250- or 500-mg daily doses of
enzastaurin with 150 mg erlotinib) are shown in Fig. 1.
Response
Although the study was not designed to assess efﬁcacy,
there was one partial response (PR) in a patient with
Table 2 Summary of all adverse events in C25% patients regardless
of drug relatedness or grade (N = 16)
Preferred term n (%)
Diarrhea 15 (93.8)
Chromaturia 12 (75.0)
Rash 11 (68.8)
Decreased appetite 9 (56.3)
Feces discolored 8 (50.0)
Nausea 8 (50.0)
Dyspnea 7 (43.8)
Fatigue 7 (43.8)
Pruritus 7 (43.8)
Dysgeusia 6 (37.5)
Abdominal pain 5 (31.3)
Back pain 5 (31.3)
Dry skin 5 (31.3)
Vomiting 5 (31.3)
Alopecia 4 (25.0)
Cough 4 (25.0)
Dermatitis acneiform 4 (25.0)
Dizziness 4 (25.0)
Epistaxis 4 (25.0)
Musculoskeletal pain 4 (25.0)
AEs with a start date during the study treatment period or within
30 days of the last dose. For patients reporting more than one
occurrence of the same AE, the earliest occurrence of the worst
severity was used for tabulation
AE adverse event; N total population size; n number of patients
1016 Cancer Chemother Pharmacol (2012) 69:1013–1020
123Table 3 Summary of patients
with non-laboratory CTCAE
maximum grade 3 or 4 possibly
related to study drug
AEs with a start date during the
study treatment period or within
30 days of the last dose. For
patients reporting more than one
occurrence of the same AE, the
earliest occurrence of the worst
severity was used for tabulation
CTCAE common terminology
criteria for adverse events
(version 3.0); N total
population; n number of
patients; GI gastrointestinal;
NOS not otherwise speciﬁed
CTCAE term, n (%) Enzastaurin ? erlotinib
Dose level 1 (N = 4) Dose level 2 (N = 12) Total (N = 16)
Grade 3 Grade 4 Grade 3 Grade 4 Grade 3 Grade 4
Patients with at least one
non-laboratory CTCAE
0 1 (25.0) 1 (8.3) 8 (66.7) 1 (6.3) 9 (56.3)
Anorexia 0 0 0 2 (16.7) 0 2 (12.5)
Ataxia 0 0 0 1 (8.3) 0 1 (6.3)
Diarrhea 0 0 2 (16.7) 2 (16.7) 2 (12.5) 2 (12.5)
Diplopia 0 0 0 1 (8.3) 0 1 (6.3)
Dizziness 0 0 1 (8.3) 0 1 (6.3) 0
Dry eye 0 0 0 1 (8.3) 0 1 (6.3)
Dry skin 0 0 0 1 (8.3) 0 1 (6.3)
Fatigue 0 0 1 (8.3) 0 1 (6.3) 0
GI—other 0 0 0 1 (8.3) 0 1 (6.3)
Hemorrhage, pulmonary, nose 0 0 0 1 (8.3) 0 1 (6.3)
Infection—other 0 0 0 1 (8.3) 0 1 (6.3)
Insomnia 0 0 0 1 (8.3) 0 1 (6.3)
Neurology—other 0 1 (25.0) 2 (16.7) 0 2 (12.5) 1 (6.3)
Ocular—other 0 0 0 1 (8.3) 0 1 (6.3)
Pain GI—abdomen NOS 0 1 (25.0) 0 0 0 1 (6.3)
Photosensitivity 0 1 (25.0) 0 0 0 1 (6.3)
Pruritus 0 1 (25.0) 0 1 (8.3) 0 2 (12.5)
Renal failure 0 0 1 (8.3) 0 1 (6.3) 0
Syncope 0 0 1 (8.3) 0 1 (6.3) 0
Vomiting 0 0 1 (8.3) 2 (16.7) 1 (6.3) 2 (12.5)
Watery eye 0 0 0 1 (8.3) 0 1 (6.3)
Table 4 Summary of enzastaurin steady-state plasma pharmacokinetic parameters following 250- or 500-mg once-daily doses of enzastaurin
with 150-mg daily doses of erlotinib
Geometric mean (CV%)
Enzastaurin LY326020 Total analyte
(enzastaurin ? LY326020)
250 mg 500 mg Enz 250 mg Enz 500 mg Enz 250 mg Enz 500 mg
N 31 231 2 31 2
Cmax,ss (nmol/L) 618 (709) 1,600 (57) 431 (806) 980 (41) 978 (797) 2,620 (44)
tmax,ss
a (h) 4.00 (4.00–6.00) 4.04 (4.00–8.00) 6.00 (0.00–6.00) 6.00 (4.00–8.00) 4.00 (4.00–6.00) 5.04 (4.00–8.00)
AUCs,ss
(nmol 9 h/L)
6,590 (412) 18,000 (71) 7,100 (890) 18,000 (44) 14,000 (598) 37,100 (51)
Cav,ss (nmol/L) 275 (412) 750 (71) 296 (890) 751 (44) 581 (598) 1,550 (51)
CLss/F (L/h) 73.6 (412) 53.8 (71) NC (NC) NC (NC) NC (NC) NC (NC)
MR NC (NC) NC (NC) 1.08 (52) 1.00 (55) NC (NC) NC (NC)
AUCs,ss area under the plasma concentration time–curve during one dosing interval at steady state; Cav,ss average drug concentration under
steady-state conditions during multiple dosing; CLss/F apparent clearance under steady-state conditions during multiple dosing; Cmax,ss maxi-
mum observed drug concentration during a dosing interval at steady state; CV coefﬁcient of variation; MR metabolic ratio; NC non-calculable;
tmax,ss time of maximum observed drug concentration during a dosing interval at steady state
a Median (range)
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123NSCLC that lasted for 12 cycles. This patient was an Asian
female non-smoker, factors known to improve response to
erlotinib [10], but her EGFR mutational status was not
known. Three patients had stable disease (SD) for
[12 months, including one patient with a decrease in
tumor size of 27%. One of these patients was actively
smoking during therapy, a factor known to decrease erl-
otinib exposure and efﬁcacy [10]. All four patients with
prolonged SD or PR had NSCLC and were female;
two were Asian and two were Caucasian. Seven patients
progressed after just two cycles, three other patients pro-
gressed before completing two cycles, and one progressed
before completing one cycle. Of the seven patients who
progressed by the ﬁrst interim scan (after completion of
two cycles), the majority had tumors other than NSCLC
(n = 4) and were smokers.
Discussion
To our knowledge, this phase I clinical trial was the ﬁrst to
combine enzastaurin with an EGFR inhibitor. The combi-
nation showed good tolerability, with no DLTs, and some
evidence of activity. We were able to safely administer the
maximum doses of both drugs without unexpected toxicity
or pharmacokinetic interactions. The recommended phase
II dose of the combination is enzastaurin 500 mg orally
daily, after a loading dose (1,125 mg on day 1 of cycle 1),
and erlotinib 150 mg orally daily.
In our study, there were no unexpected AEs with the
combination of erlotinib and enzastaurin, and those seen
had been previously documented in single-agent studies of
erlotinib or enzastaurin [8, 10]. The most common AEs in
this study, regardless of relationship to therapy, were
diarrhea, chromaturia, rash, decreased appetite, feces dis-
coloration, and nausea. The most common possibly drug-
related grade 3–4 toxicities included diarrhea, neurologic
symptoms, and vomiting. In a phase II study of enzastaurin
in advanced NSCLC, fatigue and nausea were the most
common AEs [8]. Grade 3 toxicities in that study included
ataxia, pulmonary embolism, and anemia in one patient
each, and there were two study discontinuations, one due to
grade 3 fatigue and one due to grade 1 dizziness [8]. In
advanced NSCLC, the most common AEs of erlotinib
alone include rash, diarrhea, anorexia, nausea, and fatigue
[10]. In this trial, we did not see any additive toxicity and
the regimen was well tolerated.
Table 5 Summary of erlotinib steady-state plasma pharmacokinetic
parameters following 150-mg daily doses of erlotinib with 250- or
500-mg once-daily doses of enzastaurin
Geometric mean (CV%)
150 mg erlotinib
250 mg enzastaurin 500 mg enzastaurin
n 31 1
Cmax,ss (ng/mL) 1,460 (41) 1,570 (37)
tmax,ss
a (h) 2.00 (2.00–6.02) 4.00 (2.00–6.00)
AUCs,ss (ng 9 h/mL) 24,700 (19) 26,100 (45)
Cav,ss (ng/mL) 1,030 (19) 1,090 (45)
CLss/F (L/h) 6.07 (19) 5.75 (45)
AUCs,ss area under the plasma concentration–time curve during one
dosing interval at steady state; Cav,ss average drug concentration under
steady-state conditions during multiple dosing; CLss/F apparent
clearance under steady-state conditions during multiple dosing;
Cmax,ss maximum observed drug concentration during a dosing
interval at steady state; CV coefﬁcient of variation; tmax,ss time of
maximum observed drug concentration during a dosing interval at
steady state
a Median (range)
ab
Fig. 1 Mean steady-state plasma concentration–time proﬁles of erlotinib (left panel, a) and total analyte (enzastaurin ? LY326020; right
panel, b)
1018 Cancer Chemother Pharmacol (2012) 69:1013–1020
123The pharmacokinetic parameters of erlotinib appear
similar when used in combination with 250- and 500-mg
once-daily doses of enzastaurin. The steady-state clearance
of erlotinib reported in a single-agent erlotinib study ran-
ged from 4.36 to 6.27 L/h for doses that ranged from 50 to
200 mg [19]. In this study, steady-state clearance (CLss/F)
of erlotinib was 6.07 and 5.75 L/h when given with 250-
and 500-mg once-daily enzastaurin, respectively, which is
within the range of values reported in the historical data.
The AUCs,ss of enzastaurin was 18,000 nmol 9 h/L in
this study when enzastaurin 500 mg and erlotinib 150 mg
were administered daily. This value is similar to the
23,600 nmol 9 h/L that was observed in the single-agent
study of enzastaurin at 525 mg orally daily [7]. Likewise,
in the current study, CLss/F was 53.8 L/h, which is not
notably different from the CLss/F of 40.3 L/h in the pre-
vious study of single-agent enzastaurin at 525 mg orally
daily [7]. Due to the high variability in CLss/F for both
studies (CV%[70), clearance does not appear to differ
between the two studies, suggesting that erlotinib does not
affect the pharmacokinetics of enzastaurin.
In this study, a PR was seen in one patient and pro-
longed SD was seen in three patients with NSCLC; thus, a
phase II study of the combination in advanced NSCLC was
initiated. The combination of erlotinib with other targeted
agents, particularly anti-angiogenic agents, has been
encouraging to date. For example, the combination of
bevacizumab and erlotinib versus erlotinib and placebo at
standard dosing in patients with advanced NSCLC who
progressed after ﬁrst-line chemotherapy (n[600 patients)
resulted in substantial improvements in median progres-
sion-free survival of 3.4 months versus 1.7 months
(P = 0.0001) and overall response rates of 12.6% versus
6.2%, although no overall survival beneﬁt was seen [20]. A
randomized phase II study compared erlotinib plus bev-
acizumab or chemotherapy plus bevacizumab versus che-
motherapy alone in patients with recurrent NSCLC and
found the best survival in both bevacizumab arms, but the
best tolerability in the erlotinib plus bevacizumab arm [21].
The addition of sorafenib, a multi-targeted tyrosine kinase
inhibitor with activity against VEGF receptor, to erlotinib
led to an increase in progression-free survival [22]. These
combinations are also showing efﬁcacy and tolerability in
other cancers, such as a phase II trial of erlotinib plus
bevacizumab in recurrent metastatic squamous cell carci-
noma of the head and neck [23].
This study was conducted in multiple tumor types, but
given the single-agent activity of erlotinib in NSCLC, fur-
ther development of the combination will be in NSCLC.
Although the study was not designed to assess efﬁcacy, one
of nine NSCLC patients in this study achieved a PRand four
of the nine NSCLC patients were on therapy for a prolonged
period of time (at least 12 cycles) with at least SD. Given
the tolerable toxicity proﬁle and the lack of pharmacoki-
netic interactions, the combination of erlotinib (150 mg
orally daily) and enzastaurin (500 mg orally daily) was
explored further. The phase II portion of this trial was ini-
tiated in patients with NSCLC who had previously been
treated with one or two prior chemotherapy regimens but
had no prior exposure to an EGFR-targeted agent.
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